dalteparin has been researched along with Bone Diseases, Metabolic in 3 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD." | 9.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| "We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD." | 5.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| " An initial dosage of 1." | 1.34 | Enoxaparin use in the neonatal intensive care unit: experience over 8 years. ( Chan, AK; Knoppert, DC; Lee, DS; Malowany, JI; Pepelassis, D, 2007) |
| "In contrast, LMWH, causes less osteopenia than heparin because it only decreases the rate of bone formation." | 1.30 | A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. ( Andrew, M; Hirsh, J; Muir, JM; Shaughnessy, SG; Weitz, JI; Young, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malowany, JI | 1 |
| Knoppert, DC | 1 |
| Chan, AK | 1 |
| Pepelassis, D | 1 |
| Lee, DS | 1 |
| Rodger, MA | 1 |
| Kahn, SR | 1 |
| Cranney, A | 1 |
| Hodsman, A | 1 |
| Kovacs, MJ | 1 |
| Clement, AM | 1 |
| Lazo-Langner, A | 1 |
| Hague, WM | 1 |
| Muir, JM | 1 |
| Hirsh, J | 1 |
| Weitz, JI | 1 |
| Andrew, M | 1 |
| Young, E | 1 |
| Shaughnessy, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dalteparin and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial.
Topics: Adult; Anticoagulants; Bone Density; Bone Diseases, Metabolic; Dalteparin; Female; Humans; Middle Ag | 2007 |
2 other studies available for dalteparin and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Topics: Anticoagulants; Bone Diseases, Metabolic; Catheters, Indwelling; Dose-Response Relationship, Drug; E | 2007 |
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.
Topics: Alkaline Phosphatase; Amino Acids; Animals; Biomarkers; Bone and Bones; Bone Development; Bone Disea | 1997 |